Literature DB >> 12691542

Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature.

J E Losa1, J M Miro, A Del Rio, A Moreno-Camacho, F Garcia, X Claramonte, F Marco, C A Mestres, M Azqueta, J M Gatell.   

Abstract

OBJECTIVES: To add to the limited information on infective endocarditis (IE) not related to intravenous drug abuse (IVDA) in HIV-1-infected patients.
METHODS: We have reviewed the characteristics of eight cases of IE in non-IVDA HIV-1 infected patients diagnosed in our institution between 1979 and 1999 as well as cases in the literature.
RESULTS: All our patients were male, and the mean age was 44 years (range 29-64). HIV-1 risk factors were: homosexuality in five, heterosexuality in two, and the use of blood products in one. HIV stage C was found in six cases, and the median (range) CD4 cell count was 22/microL (4-274 cells/microL). IE was caused by Enterococcus faecalis in three cases, staphylococci in two cases, and Salmonella enteritidis, viridans group streptococci and Coxiella burnetii in one case each. Three patients acquired IE while in the hospital. All IE cases involved a native valve, and underlying valve disease was found in three patients. The aortic valve was the most frequently affected (five cases). Two patients underwent surgery, with a good outcome, and one patient died. Fourteen cases of IE not related to IVDA in HIV-1-infected patients were found in the literature review. The most common causative agents were Salmonella spp. and fungi (four cases each). Two patients had prosthetic valve IE, and the mitral valve was the most frequently affected (10 cases). The remaining clinical characteristics and the outcome were similar to those in the present series.
CONCLUSIONS: IE not related to IVDA is rare in HIV-1-infected patients. In more than half of the cases, IE develops in patients with advanced HIV-1 disease. A wide etiologic range is found, reflecting different clinical and environmental conditions. None of the patients who underwent surgery died, and the overall mortality rate was not higher than in non-HIV-1-infected patients with IE.

Entities:  

Mesh:

Year:  2003        PMID: 12691542     DOI: 10.1046/j.1469-0691.2003.00505.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

Review 1.  Nontyphoidal cardiac salmonellosis: two case reports and a review of the literature.

Authors:  Daniel Ortiz; Eric M Siegal; Christopher Kramer; Bijoy K Khandheria; Ernesto Brauer
Journal:  Tex Heart Inst J       Date:  2014-08-01

2.  Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles.

Authors:  I Anguera; A Del Río; J M Miró; X Matínez-Lacasa; F Marco; J R Gumá; G Quaglio; X Claramonte; A Moreno; C A Mestres; E Mauri; M Azqueta; N Benito; C García-de la María; M Almela; M-J Jiménez-Expósito; O Sued; E De Lazzari; J M Gatell
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

3.  Complications of native and prosthetic valve infective endocarditis: update in 2006.

Authors:  Ignasi Anguera; Ana del Río; Asunción Moreno; Carlos Paré; Carlos A Mestres; José M Miró
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

4.  Concurrent aortic valvular disease and pulmonary sequestration: clinical implications.

Authors:  Dawn S Hui; David M Shavelle; Vaughn A Starnes; P Michael McFadden
Journal:  Tex Heart Inst J       Date:  2014-12-01

5.  Infective Endocarditis in Intravenous Drug Abusers.

Authors:  José M. Miró; Asuncion Moreno; Carlos A. Mestres
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

Review 6.  Mechanisms of infective endocarditis: pathogen-host interaction and risk states.

Authors:  Karl Werdan; Sebastian Dietz; Bettina Löffler; Silke Niemann; Hasan Bushnaq; Rolf-Edgar Silber; Georg Peters; Ursula Müller-Werdan
Journal:  Nat Rev Cardiol       Date:  2013-11-19       Impact factor: 32.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.